355 related articles for article (PubMed ID: 31178856)
1. Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.
Seliger B
Front Immunol; 2019; 10():999. PubMed ID: 31178856
[TBL] [Abstract][Full Text] [Related]
2. New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.
Hu-Lieskovan S; Ribas A
Cancer J; 2017; 23(1):10-22. PubMed ID: 28114250
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
Sharma P
Cancer J; 2016; 22(2):68-72. PubMed ID: 27111900
[TBL] [Abstract][Full Text] [Related]
4. Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review.
Haibe Y; El Husseini Z; El Sayed R; Shamseddine A
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32867025
[TBL] [Abstract][Full Text] [Related]
5. The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity.
Wu Z; Li S; Zhu X
Front Immunol; 2021; 12():682435. PubMed ID: 34194437
[TBL] [Abstract][Full Text] [Related]
6. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
Brown JS; Sundar R; Lopez J
Br J Cancer; 2018 Feb; 118(3):312-324. PubMed ID: 29123260
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy: weak beats strong.
Deppert W; Bruns M
Aging (Albany NY); 2016 Nov; 8(11):2607-2608. PubMed ID: 27920406
[No Abstract] [Full Text] [Related]
8. Immunotherapy and tumor microenvironment.
Tang H; Qiao J; Fu YX
Cancer Lett; 2016 Jan; 370(1):85-90. PubMed ID: 26477683
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.
Sau S; Alsaab HO; Bhise K; Alzhrani R; Nabil G; Iyer AK
J Control Release; 2018 Mar; 274():24-34. PubMed ID: 29391232
[TBL] [Abstract][Full Text] [Related]
10. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors.
Liang Y; Wang L; Ma P; Ju D; Zhao M; Shi Y
Front Immunol; 2023; 14():1308264. PubMed ID: 38077327
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Butterfield LH; Najjar YG
Nat Rev Immunol; 2024 Jun; 24(6):399-416. PubMed ID: 38057451
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers.
Yang Y; Alderman C; Sehlaoui A; Xiao Y; Wang W
Can J Gastroenterol Hepatol; 2018; 2018():9740357. PubMed ID: 30046565
[TBL] [Abstract][Full Text] [Related]
13. Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy.
Rudqvist NP; Avagyan M; Chand D
Oncoimmunology; 2023; 12(1):2275333. PubMed ID: 37937212
[TBL] [Abstract][Full Text] [Related]
14. Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications.
Bergholz JS; Wang Q; Kabraji S; Zhao JJ
Clin Cancer Res; 2020 Nov; 26(21):5557-5566. PubMed ID: 32576627
[TBL] [Abstract][Full Text] [Related]
15. Exploiting synergy: immune-based combinations in the treatment of prostate cancer.
Burotto M; Singh N; Heery CR; Gulley JL; Madan RA
Front Oncol; 2014; 4():351. PubMed ID: 25566495
[TBL] [Abstract][Full Text] [Related]
16. Combining cancer immunotherapy and targeted therapy.
Ribas A; Wolchok JD
Curr Opin Immunol; 2013 Apr; 25(2):291-6. PubMed ID: 23561594
[TBL] [Abstract][Full Text] [Related]
17. [Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application].
Zhang S; Ren S
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):645-651. PubMed ID: 28935020
[TBL] [Abstract][Full Text] [Related]
18. A Review of Ultrasound-Mediated Checkpoint Inhibitor Immunotherapy.
Rivera J; Digklia A; Christou AS; Anibal J; Vallis KA; Wood BJ; Stride E
Ultrasound Med Biol; 2024 Jan; 50(1):1-7. PubMed ID: 37798210
[TBL] [Abstract][Full Text] [Related]
19. Immune modulation during anti-cancer radio(immuno)therapy.
Irianto T; Gaipl US; Rückert M
Int Rev Cell Mol Biol; 2024; 382():239-277. PubMed ID: 38225105
[TBL] [Abstract][Full Text] [Related]
20. Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy.
Viktorsson K; Rieckmann T; Fleischmann M; Diefenhardt M; Hehlgans S; Rödel F
Strahlenther Onkol; 2023 Dec; 199(12):1091-1109. PubMed ID: 37041372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
